HLNL Stock Overview
Engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
Haleon plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£3.32 |
| 52 Week High | UK£3.44 |
| 52 Week Low | UK£3.07 |
| Beta | 0 |
| 11 Month Change | 2.97% |
| 3 Month Change | 1.56% |
| 1 Year Change | 3.54% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 10.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| HLNL | GB Personal Products | GB Market | |
|---|---|---|---|
| 7D | 2.9% | 0.3% | 1.1% |
| 1Y | 3.5% | 6.9% | 8.1% |
Return vs Industry: HLNL underperformed the UK Personal Products industry which returned 6.9% over the past year.
Return vs Market: HLNL underperformed the UK Market which returned 8.1% over the past year.
Price Volatility
| HLNL volatility | |
|---|---|
| HLNL Average Weekly Movement | 2.2% |
| Personal Products Industry Average Movement | 4.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: HLNL has not had significant price volatility in the past 3 months.
Volatility Over Time: HLNL's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1715 | 25,408 | Brian McNamara | www.haleon.com |
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues.
Haleon plc Fundamentals Summary
| HLNL fundamental statistics | |
|---|---|
| Market cap | UK£30.50b |
| Earnings (TTM) | UK£1.08b |
| Revenue (TTM) | UK£11.24b |
28.2x
P/E Ratio2.7x
P/S RatioIs HLNL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HLNL income statement (TTM) | |
|---|---|
| Revenue | UK£11.24b |
| Cost of Revenue | UK£4.28b |
| Gross Profit | UK£6.96b |
| Other Expenses | UK£5.88b |
| Earnings | UK£1.08b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 01, 2024
| Earnings per share (EPS) | 0.12 |
| Gross Margin | 61.94% |
| Net Profit Margin | 9.64% |
| Debt/Equity Ratio | 57.4% |
How did HLNL perform over the long term?
See historical performance and comparison